- Home
- PD vs VRDN Comparison
PD vs VRDN Comparison
Compare PD & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PD
- VRDN
- Stock Information
- Founded
- PD 2009
- VRDN 2006
- Country
- PD United States
- VRDN United States
- Employees
- PD N/A
- VRDN N/A
- Industry
- PD Computer Software: Prepackaged Software
- VRDN Medical Specialities
- Sector
- PD Technology
- VRDN Health Care
- Exchange
- PD Nasdaq
- VRDN Nasdaq
- Market Cap
- PD 1.5B
- VRDN 1.5B
- IPO Year
- PD 2019
- VRDN N/A
- Fundamental
- Price
- PD $15.94
- VRDN $18.66
- Analyst Decision
- PD Hold
- VRDN Strong Buy
- Analyst Count
- PD 9
- VRDN 11
- Target Price
- PD $18.33
- VRDN $38.80
- AVG Volume (30 Days)
- PD 2.6M
- VRDN 850.8K
- Earning Date
- PD 09-03-2025
- VRDN 11-11-2025
- Dividend Yield
- PD N/A
- VRDN N/A
- EPS Growth
- PD N/A
- VRDN N/A
- EPS
- PD N/A
- VRDN N/A
- Revenue
- PD $483,608,000.00
- VRDN $305,000.00
- Revenue This Year
- PD $9.50
- VRDN N/A
- Revenue Next Year
- PD $7.41
- VRDN $35,092.81
- P/E Ratio
- PD N/A
- VRDN N/A
- Revenue Growth
- PD 8.20
- VRDN 5.90
- 52 Week Low
- PD $13.70
- VRDN $9.90
- 52 Week High
- PD $21.98
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- PD 51.21
- VRDN 50.87
- Support Level
- PD N/A
- VRDN $17.91
- Resistance Level
- PD $16.68
- VRDN $20.51
- Average True Range (ATR)
- PD 0.76
- VRDN 0.93
- MACD
- PD -0.67
- VRDN -0.14
- Stochastic Oscillator
- PD 92.16
- VRDN 28.85
About PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).